BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zerizer I, Al-Nahhas A, Towey D, Tait P, Ariff B, Wasan H, Hatice G, Habib N, Barwick T. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging 2012;39:1391-9. [PMID: 22644713 DOI: 10.1007/s00259-012-2149-1] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Obrzut S, Mccammack K, Badran KW, Balistreri A, Ou E, Nguyen BJ, Hoh CK, Rose SC. Prognostic value of post-Yttrium 90 radioembolization therapy 18F-fluorodeoxyglucose positron emission tomography in patients with liver tumors. Clinical Imaging 2017;42:43-9. [DOI: 10.1016/j.clinimag.2016.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
2 Camacho JC, Kokabi N, Xing M, Schuster DM, Kim HS. PET response criteria for solid tumors predict survival at three months after intra-arterial resin-based 90Yttrium radioembolization therapy for unresectable intrahepatic cholangiocarcinoma. Clin Nucl Med 2014;39:944-50. [PMID: 25140563 DOI: 10.1097/RLU.0000000000000557] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 2.1] [Reference Citation Analysis]
3 Magnetta MJ, Ghodadra A, Lahti SJ, Xing M, Zhang D, Kim HS. Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. Abdom Radiol 2017;42:451-9. [DOI: 10.1007/s00261-016-0875-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
4 Maccauro M, Lorenzoni A, Boni G, Chiesa C, Spreafico C, Romito R, Mazzaferro V, Seregni E. Multiagent imaging of liver tumors with reference to intra-arterial radioembolization. Clin Transl Imaging 2013;1:423-32. [DOI: 10.1007/s40336-013-0040-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
5 Eldredge-Hindy H, Ohri N, Anne PR, Eschelman D, Gonsalves C, Intenzo C, Bar-Ad V, Dicker A, Doyle L, Li J, Sato T. Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography. Am J Clin Oncol 2016;39:189-95. [PMID: 24441583 DOI: 10.1097/COC.0000000000000033] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
6 Czernuszewicz TJ, Papadopoulou V, Rojas JD, Rajamahendiran RM, Perdomo J, Butler J, Harlacher M, O'Connell G, Zukić D, Aylward SR, Dayton PA, Gessner RC. A new preclinical ultrasound platform for widefield 3D imaging of rodents. Rev Sci Instrum 2018;89:075107. [PMID: 30068108 DOI: 10.1063/1.5026430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Eaton BR, Kim HS, Schreibmann E, Schuster DM, Galt JR, Barron B, Kim S, Liu Y, Landry J, Fox T. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma. J Vasc Interv Radiol 2014;25:288-95. [PMID: 24269792 DOI: 10.1016/j.jvir.2013.08.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
8 Swinburne NC, Biederman DM, Besa C, Tabori NE, Fischman AM, Patel RS, Nowakowski FS, Gunasekaran G, Schwartz ME, Lookstein RA, Kim E. Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: Review of Safety, Response Evaluation Criteria in Solid Tumors 1.1 Imaging Response and Survival. Cancer Biotherapy and Radiopharmaceuticals 2017;32:161-8. [DOI: 10.1089/cbr.2017.2189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
9 Rojas JD, Papadopoulou V, Czernuszewicz TJ, Rajamahendiran RM, Chytil A, Chiang YC, Chong DC, Bautch VL, Rathmell WK, Aylward S, Gessner RC, Dayton PA. Ultrasound Measurement of Vascular Density to Evaluate Response to Anti-Angiogenic Therapy in Renal Cell Carcinoma. IEEE Trans Biomed Eng 2019;66:873-80. [PMID: 30059292 DOI: 10.1109/TBME.2018.2860932] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
10 Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging. 2015;42:386-396. [PMID: 25359635 DOI: 10.1007/s00259-014-2944-y] [Cited by in Crossref: 96] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
11 Cingarlini S, Ortolani S, Salgarello M, Butturini G, Malpaga A, Malfatti V, DʼOnofrio M, Davì MV, Vallerio P, Ruzzenente A, Capelli P, Citton E, Grego E, Trentin C, De Robertis R, Scarpa A, Bassi C, Tortora G. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions. Pancreas 2017;46:42-7. [PMID: 27906872 DOI: 10.1097/MPA.0000000000000745] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
12 Binderup T, Knigge U, Johnbeck CB, Loft A, Berthelsen AK, Oturai P, Mortensen J, Federspiel B, Langer SW, Kjaer A. 18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study. J Nucl Med 2021;62:808-15. [PMID: 33067340 DOI: 10.2967/jnumed.120.244798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
13 Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, Gnesin S, Bodei L, Kracmerova T, Luster M, Garin E, Herrmann K. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 2022. [PMID: 35146577 DOI: 10.1007/s00259-021-05600-z] [Reference Citation Analysis]
14 Bastiaannet R, Lodge MA, de Jong HW, Lam MG. The Unique Role of Fluorodeoxyglucose-PET in Radioembolization. PET Clinics 2019;14:447-57. [DOI: 10.1016/j.cpet.2019.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 van Roekel C, Jongen JMJ, Smits MLJ, Elias SG, Koopman M, Kranenburg O, Borel Rinkes IHM, Lam MGEH. Mode of progression after radioembolization in patients with colorectal cancer liver metastases. EJNMMI Res 2020;10:107. [PMID: 32960390 DOI: 10.1186/s13550-020-00697-z] [Reference Citation Analysis]
16 Sabet A, Ahmadzadehfar H, Bruhman J, Sabet A, Meyer C, Wasmuth JC, Pieper CC, Biersack HJ, Ezziddin S. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET. Nuklearmedizin. 2014;53:39-45. [PMID: 24777354 DOI: 10.3413/nukmed-0622-13-09] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
17 Hunt S, Zandifar A, Alavi A. Molecular imaging in management of colorectal metastases by the interventional oncologist. International Journal of Hyperthermia 2022;39:675-81. [DOI: 10.1080/02656736.2021.1998657] [Reference Citation Analysis]
18 Soydal C, Kucuk NO, Balci D, Gecim E, Bilgic S, Elhan AH. Prognostic Importance of the Presence of Early Metabolic Response and Absence of Extrahepatic Metastasis After Selective Internal Radiation Therapy in Colorectal Cancer Liver Metastasis. Cancer Biother Radiopharm 2016;31:342-6. [PMID: 27831761 DOI: 10.1089/cbr.2016.2105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
19 Grut H, Revheim M, Line P, Dueland S. Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation. Nuclear Medicine Communications 2018;39:621-7. [DOI: 10.1097/mnm.0000000000000843] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
20 Rani SD, Nemanich ST, Fettig N, Shoghi KI. Kinetic analysis of FDG in rat liver: effect of dietary intervention on arterial and portal vein input. Nucl Med Biol 2013;40:537-46. [PMID: 23454249 DOI: 10.1016/j.nucmedbio.2013.01.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
21 Kennedy AS, Ball DS, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kanani S, Nutting CW, Moeslein FM, Putnam SG 3rd, Rose SC, Savin MA, Schirm S, Sharma NK, Wang EA. Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases. J Gastrointest Oncol 2015;6:594-604. [PMID: 26697190 DOI: 10.3978/j.issn.2078-6891.2015.082] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
22 Eo JS, Paeng JC, Lee DS. Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation. World J Gastroenterol 2014; 20(18): 5375-5388 [PMID: 24833867 DOI: 10.3748/wjg.v20.i18.5375] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
23 Aarntzen EH, Heijmen L, Oyen WJ. 18 F-FDG PET/CT in Local Ablative Therapies: A Systematic Review. J Nucl Med 2018;59:551-6. [DOI: 10.2967/jnumed.117.198184] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Bagni O, Filippi L, Schillaci O. 18F-FDG PET-derived parameters as prognostic indices in hepatic malignancies after 90Y radioembolization: is there a role? Eur J Nucl Med Mol Imaging 2015;42:367-9. [PMID: 25476259 DOI: 10.1007/s00259-014-2966-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
25 Jongen JM, Rosenbaum CE, Braat MN, van den Bosch MA, Sze DY, Kranenburg O, Borel Rinkes IH, Lam MG, van den Hoven AF. Anatomic versus Metabolic Tumor Response Assessment after Radioembolization Treatment. Journal of Vascular and Interventional Radiology 2018;29:244-253.e2. [DOI: 10.1016/j.jvir.2017.09.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
26 Samim M, El-Haddad GE, Molenaar IQ, Prevoo W, van den Bosch MA, Alavi A, Lam MG. [18F]Fluorodeoxyglucose PET for Interventional Oncology in Liver Malignancy. PET Clin 2014;9:469-95, vi. [PMID: 26050948 DOI: 10.1016/j.cpet.2014.07.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
27 Grassi I, Morigi JJ, Nanni C, Fanti S. FDG and other radiopharmaceuticals in the evaluation of liver lesions. Clin Transl Imaging 2014;2:115-27. [DOI: 10.1007/s40336-014-0059-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol 2016;89:20150943. [PMID: 26943239 DOI: 10.1259/bjr.20150943] [Cited by in Crossref: 47] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
29 Rosenbaum CE, Verkooijen HM, Lam MG, Smits ML, Koopman M, van Seeters T, Vermoolen MA, van den Bosch MA. Radioembolization for Treatment of Salvage Patients with Colorectal Cancer Liver Metastases: A Systematic Review. J Nucl Med 2013;54:1890-5. [DOI: 10.2967/jnumed.113.119545] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
30 Sofocleous CT, Garcia AR, Pandit-taskar N, Do KG, Brody LA, Petre EN, Capanu M, Longing AP, Chou JF, Carrasquillo JA, Kemeny NE. Phase I Trial of Selective Internal Radiation Therapy for Chemorefractory Colorectal Cancer Liver Metastases Progressing After Hepatic Arterial Pump and Systemic Chemotherapy. Clinical Colorectal Cancer 2014;13:27-36. [DOI: 10.1016/j.clcc.2013.11.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
31 Annunziata S, Treglia G, Caldarella C, Galiandro F. The role of 18F-FDG-PET and PET/CT in patients with colorectal liver metastases undergoing selective internal radiation therapy with yttrium-90: a first evidence-based review. ScientificWorldJournal 2014;2014:879469. [PMID: 24672385 DOI: 10.1155/2014/879469] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
32 Vouche M, Salem R, Miller FH, Lemort M, Vanderlinden B, De Becker D, Hendlisz A, Flamen P. Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance. Clin Imaging 2015;39:454-62. [PMID: 25724225 DOI: 10.1016/j.clinimag.2014.12.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Guo Y, Yaghmai V, Salem R, Lewandowski RJ, Nikolaidis P, Larson AC, Miller FH. Imaging tumor response following liver-directed intra-arterial therapy. Abdom Imaging. 2013;38:1286-1299. [PMID: 23807705 DOI: 10.1007/s00261-013-0017-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
34 Braat AJ, Huijbregts JE, Molenaar IQ, Borel Rinkes IH, van den Bosch MA, Lam MG. Hepatic radioembolization as a bridge to liver surgery. Front Oncol. 2014;4:199. [PMID: 25126539 DOI: 10.3389/fonc.2014.00199] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
35 Shady W, Sotirchos VS, Do RK, Pandit-Taskar N, Carrasquillo JA, Gonen M, Sofocleous CT. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres. AJR Am J Roentgenol 2016;207:661-70. [PMID: 27384594 DOI: 10.2214/AJR.15.15202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
36 Bijlstra OD, Boreel MME, van Mossel S, Burgmans MC, Kapiteijn EHW, Oprea-lager DE, Rietbergen DDD, van Velden FHP, Vahrmeijer AL, Swijnenburg R, Mieog JSD, de Geus-oei L. The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review. Diagnostics 2022;12:715. [DOI: 10.3390/diagnostics12030715] [Reference Citation Analysis]
37 Filippi L, Pelle G, Cianni R, Scopinaro F, Bagni O. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma. Nucl Med Biol. 2015;42:59-64. [PMID: 25213104 DOI: 10.1016/j.nucmedbio.2014.08.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
38 Grut H, Dueland S, Line PD, Revheim ME. The prognostic value of 18F–FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging 2018;45:218-25. [DOI: 10.1007/s00259-017-3843-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
39 Entezari P, Gabr A, Salem R, Lewandowski RJ. Yttrium-90 for colorectal liver metastasis - the promising role of radiation segmentectomy as an alternative local cure. International Journal of Hyperthermia 2022;39:620-6. [DOI: 10.1080/02656736.2021.1933215] [Reference Citation Analysis]
40 Ceelen F, Theisen D, de Albéniz XG, Auernhammer CJ, Haug AR, D'Anastasi M, Paprottka PM, Rist C, Reiser MF, Sommer WH. Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases? J Magn Reson Imaging 2015;41:361-8. [PMID: 24446275 DOI: 10.1002/jmri.24569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
41 Edalat F, Camacho JC, Kokabi N, Kendi AT, Galt JR, Kim HS. Standardized Added Metabolic Activity Predicts Survival After Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver. Clin Nucl Med 2016;41:e76-81. [PMID: 26447380 DOI: 10.1097/RLU.0000000000000991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Salem ME, Jain N, Dyson G, Taylor S, El-Refai SM, Choi M, Shields AF, Critchfield J, Philip PA. Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization. ISRN Oncol 2013;2013:538376. [PMID: 24167742 DOI: 10.1155/2013/538376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Sabet A, Meyer C, Aouf A, Sabet A, Ghamari S, Pieper CC, Mayer K, Biersack HJ, Ezziddin S. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. Eur J Nucl Med Mol Imaging 2015;42:370-6. [PMID: 25351506 DOI: 10.1007/s00259-014-2935-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
44 Xia Q, Liu J, Wu C, Song S, Tong L, Huang G, Feng Y, Jiang Y, Liu Y, Yin T, Ni Y. Prognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis. Cancer Imaging. 2015;15:19. [PMID: 26589835 DOI: 10.1186/s40644-015-0055-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
45 Seyal AR, Parekh K, Arslanoglu A, Gonzalez-guindalini FD, Tochetto SM, Velichko YS, Yaghmai V. Performance of tumor growth kinetics as an imaging biomarker for response assessment in colorectal liver metastases: correlation with FDG PET. Abdom Imaging 2015;40:3043-51. [DOI: 10.1007/s00261-015-0546-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
46 Deipolyi AR, England RW, Ridouani F, Riedl CC, Kunin HS, Boas FE, Yarmohammadi H, Sofocleous CT. PET/CT Imaging Characteristics After Radioembolization of Hepatic Metastasis from Breast Cancer.Cardiovasc Intervent Radiol. 2020;43:488-494. [PMID: 31732778 DOI: 10.1007/s00270-019-02375-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
47 Padia SA, Lewandowski RJ, Johnson GE, Sze DY, Ward TJ, Gaba RC, Baerlocher MO, Gates VL, Riaz A, Brown DB, Siddiqi NH, Walker TG, Silberzweig JE, Mitchell JW, Nikolic B, Salem R. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. Journal of Vascular and Interventional Radiology 2017;28:1-15. [DOI: 10.1016/j.jvir.2016.09.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
48 Dendy MS, Ludwig JM, Kim HS. Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis. Oncotarget 2017;8:37912-22. [PMID: 28415671 DOI: 10.18632/oncotarget.16007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
49 Evangelista L, Ravelli I, Bignotto A, Cecchin D, Zucchetta P. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review. Clin Imaging 2020;67:113-6. [PMID: 32559681 DOI: 10.1016/j.clinimag.2020.05.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
50 Rojas JD, Dayton PA. In Vivo Molecular Imaging Using Low-Boiling-Point Phase-Change Contrast Agents: A Proof of Concept Study. Ultrasound in Medicine & Biology 2019;45:177-91. [DOI: 10.1016/j.ultrasmedbio.2018.08.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
51 Deipolyi AR, Riedl CC, Bromberg J, Chandarlapaty S, Klebanoff CA, Sofocleous CT, Yarmohammadi H, Brody LA, Boas FE, Ziv E. Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study. J Vasc Interv Radiol 2018;29:1226-35. [PMID: 30078647 DOI: 10.1016/j.jvir.2018.04.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
52 Zhen Y, Liu B, Chang Z, Ren H, Liu Z, Zheng J. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. Onco Targets Ther 2019;12:4489-98. [PMID: 31239717 DOI: 10.2147/OTT.S202875] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
53 Sahani DV, Bajwa MA, Andrabi Y, Bajpai S, Cusack JC. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. Ann Surg. 2014;259:861-872. [PMID: 24509207 DOI: 10.1097/sla.0000000000000525] [Cited by in Crossref: 41] [Cited by in F6Publishing: 17] [Article Influence: 5.1] [Reference Citation Analysis]
54 Shady W, Kishore S, Gavane S, Do RK, Osborne JR, Ulaner GA, Gonen M, Ziv E, Boas FE, Sofocleous CT. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0. Eur J Radiol 2016;85:1224-31. [PMID: 27161074 DOI: 10.1016/j.ejrad.2016.03.029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
55 Jreige M, Mitsakis P, Van Der Gucht A, Pomoni A, Silva-Monteiro M, Gnesin S, Boubaker A, Nicod-Lalonde M, Duran R, Prior JO, Denys A, Schaefer N. 18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2017;44:1215-1222. [PMID: 28233086 DOI: 10.1007/s00259-017-3653-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
56 Sofocleous CT, Violari EG, Sotirchos VS, Shady W, Gonen M, Pandit-Taskar N, Petre EN, Brody LA, Alago W, Do RK, D'Angelica MI, Osborne JR, Segal NH, Carrasquillo JA, Kemeny NE. Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes. Clin Colorectal Cancer 2015;14:296-305. [PMID: 26277696 DOI: 10.1016/j.clcc.2015.06.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
57 Fendler WP, Philippe Tiega DB, Ilhan H, Paprottka PM, Heinemann V, Jakobs TF, Bartenstein P, Hacker M, Haug AR. Validation of Several SUV-Based Parameters Derived from 18 F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer. J Nucl Med 2013;54:1202-8. [DOI: 10.2967/jnumed.112.116426] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
58 Harris JL, Stocum M, Roberts L, Jiang C, Lin J, Sprott K. Quest for the Ideal Cancer Biomarker: An Update on Progress in Capture and Characterization of Circulating Tumor Cells: The Ideal Cancer Biomarker. Drug Dev Res 2013;74:138-47. [DOI: 10.1002/ddr.21072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
59 Turkmen C, Ucar A, Poyanli A, Vatankulu B, Ozkan G, Basaran M, Serin K, Sanli Y, Adalet I. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease. Cancer Biother Radiopharm 2013;28:534-40. [PMID: 23647219 DOI: 10.1089/cbr.2012.1455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
60 Kishore SA, Drabkin MJ, Sofocleous CT. Fluorodeoxyglucose-PET for Ablation Treatment Planning, Intraprocedural Monitoring, and Response. PET Clin 2019;14:427-36. [PMID: 31472740 DOI: 10.1016/j.cpet.2019.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
61 Amthauer H, Ulrich G, Grosser OS, Ricke J. Reply: Pretreatment Dosimetry in HCC Radioembolization with 90 Y Glass Microspheres Cannot Be Invalidated with a Bare Visual Evaluation of 99m Tc-MAA Uptake of Colorectal Metastases Treated with Resin Microspheres. J Nucl Med 2014;55:1216-8. [DOI: 10.2967/jnumed.114.138198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]